In summary, our meta-analysis demonstrates that SGLT2 inhibitors significantly reduce the risk of AF/AFL but have no notable impact on the risk of VT, VF, and sinus bradycardia. The gene discussed is SLC5A2; the disease is ventricular fibrillation.